National Conference on Pharma Industry: Whither To?

28 June, 2013, Hotel Taj Deccan, Hyderabad

 | Registration Form | Sponsorship Details

Pharmaceuticals industry has recorded robust growth over last decade, even bucking the global slowdown or inflationary pressures that impacted all other sectors of industry.

According to one study, industry is likely to record CAGR of 14% in the years to come and the size of industry is likely to reach $50 billion by the year 2015. Growth of the sector has been driven by numerous advantages enjoyed by Indian pharma sector. These include availability of technical expertise, significant cost advantages, increase in general income levels, growth in generics, several drugs going off-patent and global preference for generic drugs.

Share of Indian pharma companies in total approvals of generic drugs in US has been on the rise. Formulation exports from India specially generic drugs grew at 21% CAGR between 2005-06 and 2010-11. With several drugs set to lose patent exclusivity by the year 2015, growth momentum in Indian drugs’ exports is likely to continue over next five years.

Recently pharma industry has also witnessed several important developments. These include significant judgements on issues related to IP rights, pharma pricing policy deliberations and acquisition of several Indian pharma firms by overseas investors.
 

The Conference would endeavour to bring together all stakeholders connected with the pharma sector and chart a fresh path for the industry so as to maintain its growth momentum and achieve higher goals.

Mr Srikant Jena, Hon’ble Union Minister of State (I/C), Ministry of Chemicals & Fertilizers and Ms Geetha Reddy, Hon’ble Minister for Large Industries, Government of Andhra Pradesh have been approached with a request to address the inaugural session of the Conference.

Conference would also be joined by several senior officials of Central & State Governments, Research Institutes, Intellectual Property experts and others associated with pharma industry.
 

ISSUES FOR DISCUSSION  

  • New Drug Price Control Order
  • Impact of Compulsory Licensing
  • Clinical Trial Regulations in India
  • Intellectual Property Regime for Pharma Sector in India
  • Ecosystem for Pharma Mergers & Acquisitions

WHO SHOULD ATTEND

- Policy Makers
- Regulators
- Decision makers from Pharma Industry (MDs/ CEOs/ COOs)
- Bulk drug manufacturers
- Pharma exporters
- Administrators of Clinical Establishments (Hospitals/ Nursing Homes/ Pharmacies etc)
- Research Institutions
- Health policy experts
- Pharma/ Medical equipment makers and suppliers
- Healthcare consultants
- Bankers/ venture capitalists
 

Registration Fees: 

  • Rs.2000/- per delegate (Non-members) :
  • Rs. 1500/- per delegate (ASSOCHAM Members) :
  • Academics & Students: Rs.1000/- per delegate